Copied
 
 
2023, DKK
13.06.2024
Bruttoresultat

2.352'

Primær drift

-17.507'

Årets resultat

-19.125'

Aktiver

35.970'

Kortfristede aktiver

4.418'

Egenkapital

12.385'

Afkastningsgrad

-49 %

Soliditetsgrad

34 %

Likviditetsgrad

103 %

Resultat
13.06.2024
Årsrapport
2023
13.06.2024
2022
02.06.2023
2021
25.05.2022
2020
26.04.2021
2019
17.09.2020
2018
28.06.2019
2017
19.06.2018
2016
15.06.2017
Nettoomsætning
Bruttoresultat2.352.4913.232.6173.992.2146.394.3835.736.7766.084.4544.342.9381.973.596
Resultat af primær drift-17.506.830-11.084.452-7.266.873-1.024.432-1.181.031-500.725-613.810-499.140
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter20.23617.221103.8770319789166.667
Finansieringsomkostninger-2.265.880-47.021-1.941.777-227.902-293.499-103.112-132.796-167.042
Andre finansielle omkostninger00000000
Resultat før skat-19.752.474-11.114.252-9.104.773-1.252.334-1.474.499-603.740-746.517-499.515
Resultat-19.124.815-9.679.595-7.079.752-978.100-1.151.801-462.187-582.787-389.776
Forslag til udbytte00000000
Aktiver
13.06.2024
Årsrapport
2023
13.06.2024
2022
02.06.2023
2021
25.05.2022
2020
26.04.2021
2019
17.09.2020
2018
28.06.2019
2017
19.06.2018
2016
15.06.2017
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 1.326.9162.013.9563.330.145718.120766.484195.911638.787645.309
Likvider3.091.1666.401.9199.992.6381.362.457632.5312.795.0651.602.6901.308.285
Kortfristede aktiver4.418.0838.415.87513.322.7832.080.5771.399.0152.990.9762.241.4771.953.594
Immaterielle aktiver og goodwill31.551.69736.844.73733.415.72423.804.94617.266.18019.766.26713.994.1069.171.434
Finansielle anlægsaktiver000000018.000
Materielle aktiver0111.547144.61030.51622.4736.21811.5263.235
Langfristede aktiver31.551.69736.956.28433.560.33423.835.46217.288.65319.772.48514.005.6329.192.669
Aktiver35.969.78045.372.16046.883.11725.916.03918.687.66822.763.46116.247.10911.146.263
Aktiver
13.06.2024
Passiver
13.06.2024
Årsrapport
2023
13.06.2024
2022
02.06.2023
2021
25.05.2022
2020
26.04.2021
2019
17.09.2020
2018
28.06.2019
2017
19.06.2018
2016
15.06.2017
Forslag til udbytte00000000
Egenkapital12.384.75616.382.90220.604.0184.105.2655.083.3656.235.1666.697.3536.080.302
Hensatte forpligtelser00457.2991.507.9781.782.2121.672.0981.813.6511.967.274
Langfristet gæld til banker00000000
Anden langfristet gæld733.8541.742.2951.359.9691.291.9821.235.6711.149.879
Leverandører af varer og tjenesteydelser1.086.254870.7511.531.275196.810390.40099.43933.657354.601
Kortfristede forpligtelser4.300.1297.090.53325.087.94618.173.87610.132.37213.564.2156.500.4341.948.808
Gældsforpligtelser23.585.02428.989.25825.821.80020.302.79611.822.09114.856.1977.736.1053.098.687
Forpligtelser23.585.02428.989.25825.821.80020.302.79611.822.09114.856.1977.736.1053.098.687
Passiver35.969.78045.372.16046.883.11725.916.03918.687.66822.763.46116.247.10911.146.263
Passiver
13.06.2024
Nøgletal
13.06.2024
Årsrapport
2023
13.06.2024
2022
02.06.2023
2021
25.05.2022
2020
26.04.2021
2019
17.09.2020
2018
28.06.2019
2017
19.06.2018
2016
15.06.2017
Afkastningsgrad -48,7 %-24,4 %-15,5 %-4,0 %-6,3 %-2,2 %-3,8 %-4,5 %
Dækningsgrad Na.Na.Na.Na.Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -154,4 %-59,1 %-34,4 %-23,8 %-22,7 %-7,4 %-8,7 %-6,4 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal -772,6 %-23.573,4 %-374,2 %-449,5 %-402,4 %-485,6 %-462,2 %-298,8 %
Soliditestgrad 34,4 %36,1 %43,9 %15,8 %27,2 %27,4 %41,2 %54,6 %
Likviditetsgrad 102,7 %118,7 %53,1 %11,4 %13,8 %22,1 %34,5 %100,2 %
Resultat
13.06.2024
Gæld
13.06.2024
Årsrapport
13.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 13.06.2024)
Beretning
13.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-05-07
Ledelsespåtegning:MANAGEMENT’S STATEMENTToday, the Executive Board and Board of Directors have considered and adopted the Annual Report of BRAIN+ A/S forthe financial year January 1st 2023 - December 31st 2023. The Annual Report is presented in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the assets, liabilities and financial position of theCompany at December 31st 2023 and of the results of the Company’s operations and cash flow for the financial yearJanuary 1st 2023 - December 31st 2023. In our opinion, the Management Commentary includes a true and fair account of the matters addressed therein. We recommend that the Annual Report be adopted at the Annual General Meeting.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesBrain+ is at the forefront of developing health tech solutions which can be certified as medical software for betterdementia management. The company aims to become the leading global dementia health tech provider with a vision toservice several million people affected by dementia by 2030. The company’s dementia activities build on its legacy of developing gamified brain training software, its in-houseexpertise in medical device development and neuroscience combined with a broad international network ofcollaborations with leading experts in brain functioning and dementia.  With a focus on developing health tech solutionsfor people with dementia which have an outset in validated and recognized analogue methods for diagnosing andpreventing cognitive decline, Brain+ has developed three medical software platforms: Software-based CognitiveStimulation Therapy (CST), Computerized Cognitive Training (CCT) and Starry Night, a software tool for detection of earlyindications of dementia. From these health tech platforms, we are developing three specific products and one technology:CST-Assistant (v1. 0 commercially available, v2. 0 in regulatory phase with expected commercial release in2024): A health tech software product to support scalable and high-quality delivery of group CST via a readilyaccessible preparation system, content adaptability and a standardized delivery form, which lessens thedependence of CST performance on therapists. CST-Home Care (In late pilot phase development): Intended for use to extend and scale the delivery of CST to ahome setting, enabling broader access to the therapy for a larger dementia population at limited costs. CST/CCT Combination Product: Tailored for individuals with Mild Cognitive Impairment, combining CognitiveStimulation Therapy with Computerized Cognitive Training to improve cognitive function and potentially delay thetransition to dementia. Starry Night: A software based test designed to detect early signs of cognitive decline and enable early targetedintervention and treatment. In late 2022, Brain+ launched the initial commercial version 1. 0 of the CST-Assistant to gauge market reception andgather crucial feedback from early adopters. This marked the beginning of Brain+'s shift from solely a development-oriented entity to a comprehensive health tech company, culminating in the creation of an enhanced v2. 0 of theproduct. As Brain+ broadens its product range to introduce CST into patients' homes, the company remains committed toproviding innovative and convenient solutions that enhance patient well-being. 